H.C. Wainwright lowered the firm’s price target on Invivyd (IVVD) to $10 from $15 and keeps a Buy rating on the shares following the Q3 report. The firm expects expect the launch of Pemgarda, which is off to a slower than expected start, to accelerate in 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IVVD:
- Invivyd’s Q3 2024: Revenue Growth and Strategic Developments
- Invivyd reports Q3 EPS (51c) vs (36c) last year
- Invivyd announces NEJM published letter to editor on PEMGARDA
- Invivyd announces manuscript preprint conveying data from CANOPY Phase 3 trial
- IVVD Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
